Although somatic mutations in these cancer types (in genes including TP53, PIK3CA, NRAS, PTEN, and BRAF) have similarities to those oncogenic mutations found in human cancers, veterinary clinical trials still need to be performed to confirm if they respond to targeted inhibition. This evidence concerns the gene TP53 and cancer.